Mostrar el registro sencillo del ítem

dc.contributor.authorPiñon Esteban, Miguel Angel 
dc.contributor.authorParedes Galán, Emilio 
dc.contributor.authorACUÑA PAIS, BEATRIZ 
dc.contributor.authorRaposeiras Roubín, Sergio 
dc.contributor.authorCASQUERO VILLACORTA, ELENA 
dc.contributor.authorFerrero Martinez, Ana Isabel
dc.contributor.authorTORRES TORRES, IVETT GUADALUPE 
dc.contributor.authorLegarra Calderón, Juan José
dc.contributor.authorPradas Montilla, Gonzalo 
dc.contributor.authorBarreiro-Morandeira, F.
dc.contributor.authorRodríguez Pascual, Carlos 
dc.date.accessioned2021-11-23T09:12:49Z
dc.date.available2021-11-23T09:12:49Z
dc.date.issued2019
dc.identifier.issn1569-9293
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31220291es]bi
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15707
dc.description.abstractOBJECTIVES: Frailty syndrome predicts adverse outcomes after surgical aortic valve replacement. However, disability or comorbidity is frequently associated with preoperative frailty evaluation. The effects of these domains on early and late outcomes were analysed. METHODS: A prospective study including patients aged >/=75 years with symptomatic severe aortic stenosis who received aortic valve replacement with or without coronary artery bypass grafting was conducted. We used the Cardiovascular Health Study Frailty Phenotype to assess frailty, the Lawton-Brody index to define disability and the Charlson comorbidity index (CCI) to evaluate comorbidity. RESULTS: Frailty was identified in 57 (31%), dependence in 18 (9.9%) and advanced comorbidity (CCI >/= 4) in 67 (36.6%) of the 183 enrolled patients. Operative mortality (1.6%), transfusion rate and duration of stay increased in patients with CCI >/=4 (P < 0.005). There was a non-significant trend for these adverse outcomes among the frail patients. Follow-up was achieved in all patients (median/interquartile range 869/699-1099 days). Kaplan-Meier univariable analysis showed a reduced survival rate for frail and dependent patients and for those with multiple comorbidities (P < 0.05). According to multivariable analysis, frailty and comorbidity were independent risk factors for 1-year mortality, while disability and comorbidity, but not frailty, were risk factors for 3-year mortality (P < 0.05). CONCLUSIONS: Surgical aortic valve replacement in patients aged >/=75 years is a safe procedure with low mortality rates. Operative outcomes are mainly affected by comorbidities. The main influence of survival occurs throughout the first year, and an improved functional status prevents any progression towards disabilities, which could potentially benefit long-term outcomes. CLINICAL TRIAL REGISTRATION NUMBER: NCT02745314.es
dc.language.isoenges
dc.subject.meshRisk Factors*
dc.subject.meshRisk Assessment*
dc.subject.meshAortic Valve Stenosis*
dc.subject.meshHumans*
dc.subject.meshHeart Valve Prosthesis*
dc.subject.meshTreatment Outcome*
dc.subject.meshHealth Status*
dc.subject.meshProspective Studies*
dc.subject.meshKaplan-Meier Estimate*
dc.subject.meshGeriatric Assessment*
dc.subject.meshSurvival Rate*
dc.subject.meshAged*
dc.titleFrailty, disability and comorbidity: different domains lead to different effects after surgical aortic valve replacement in elderly patientses
dc.typeArtigoes
dc.authorsophosPinon, M.
dc.authorsophosParedes, E.
dc.authorsophosAcuna, B.
dc.authorsophosRaposeiras, S.
dc.authorsophosCasquero, E.
dc.authorsophosFerrero, A.
dc.authorsophosTorres, I.
dc.authorsophosLegarra, J. J.
dc.authorsophosPradas, G.
dc.authorsophosBarreiro-Morandeira, F.
dc.authorsophosRodriguez-Pascual, C.
dc.identifier.doi10.1093/icvts/ivz093
dc.identifier.pmid31220291
dc.identifier.sophos31407
dc.issue.number3es
dc.journal.titleInteract Cardiovasc Thorac Surges
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Cardioloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Xeriatríaes
dc.page.initial371es
dc.page.final377es
dc.relation.publisherversionhttps://watermark.silverchair.com/ivz093.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAp8wggKbBgkqhkiG9w0BBwagggKMMIICiAIBADCCAoEGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM78EmRvNVOH9H9hSlAgEQgIICUpQO16Z5KVE7SoMIYNNfs8VneTwRoCVULKa05RQUktJBZrsslhfypv7xgKaYTYGMV8jV7aOESijhN7qssZIPm9RH1aGzR9m0bdTKTNIUjjGdj15vsBZ9NEqUmeZ6HkMUfXxxl2-2NKdLybosRMv9LMEfA80SUCC0Ez0SxveOrUIyr0p1JOrgFbfYzxyev7eHppxVa9IvQjdQ5V9UuQnY786MXyDtoyWpp_EYNII5Wi8_QLrO60vb9x_w0LPpRKIoxwe2mqKGTvZ81IqoM17IHPNzTS7-DkdI1shpU5SML7xjnD4mxSuLFD2hnWG5uqjubp1hL8pyNqwnOkG_OMMEubViaQB7ttlObOQD10YEBDhm0r-hqMh2sKiOf_8wBLABAjzBpR4t2CMsAoq4fGSjKWJpelwCzNuQH6VZ5AFn07XywiYKFGKokadbmUOkdv6-gRNC0sHTPbWHiBgDQ3c2yCSne_3alyNxQknDfEB5J9LoD1Je69xyAImLPqSV7VUhHU1lrjCdgW6NmA-9QmyMhGsJ-QsbFCumdsUlvnmXPX5rExS7SzIUzJq8focojxzJdPTznr_3ZjtyEGEckaMCK7TpB2h6L-mZSPSYO_R-6LIkQRXhk9l3dALIzeKYGbQZCvHBRsnnwJZUnAH8KToCqXlHF3u_xgOF3WMSaV56G02tQh84A9WQD_vfBH3cCQZ6Usfxo6T5IKWJ_oUyhX9NncJ0xOMTJ24wsGzAziEjfQ7vNI2psclkuS8qbLXtFhe2FX1q2egd3Qgc4xqDsA4TbZSKWwes
dc.rights.accessRightsembargoedAccesses
dc.subject.decsestado de salud*
dc.subject.decsprótesis valvulares cardíacas*
dc.subject.decsresultado del tratamiento*
dc.subject.decsanciano*
dc.subject.decstasa de supervivencia*
dc.subject.decsestimación de Kaplan-Meier*
dc.subject.decsfactores de riesgo*
dc.subject.decsestudios prospectivos*
dc.subject.decsevaluación de riesgos*
dc.subject.decshumanos*
dc.subject.decsestenosis de la válvula aórtica*
dc.subject.decsevaluación geriátrica*
dc.subject.keywordCHUVIes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number29es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem